Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$136.46 USD
+0.65 (0.48%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $136.61 +0.15 (0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Ascendis Pharma A/S (ASND) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$180.09 | $262.00 | $140.00 | 32.60% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Ascendis Pharma A/S comes to $180.09. The forecasts range from a low of $140.00 to a high of $262.00. The average price target represents an increase of 32.16% from the last closing price of $136.27.
Analyst Price Targets (11)
Broker Rating
Ascendis Pharma A/S currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on 14 recommendations.
Of the 12 recommendations deriving the current ABR, 10 are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 78.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ASND.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 11 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.43 | 1.46 | 1.46 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Cowen & Co. | Yaron Werber | Hold | Strong Buy |
5/3/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/1/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
3/15/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
2/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 12 |
Average Target Price | $180.09 |
LT Growth Rate | 33.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -1.51 |